Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bisoprolol
Drug ID BADD_D00277
Description Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs.[A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.[A180562]
Indications and Usage For management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
Marketing Status Prescription; Discontinued
ATC Code C07AB07
DrugBank ID DB00612
KEGG ID D02342
MeSH ID D017298
PubChem ID 2405
TTD Drug ID D0K3ZR
NDC Product Code Not Available
Synonyms Bisoprolol | Bisoprolol Fumarate (1:1) Salt, (+-)-Isomer | Bisoprolol Fumarate (2:1) Salt, (+-)-Isomer | Bisoprolol Hydrochloride | Hydrochloride, Bisoprolol | Bisoprolol Methanesulfonate Salt | Bisoprolol, (+-)-Isomer | Bisoprolol, Fumarate (1:1) Salt | Bisoprolol, Fumarate (2:1) Salt | CL-297939 | CL 297939 | CL297939 | Concor | EMD-33512 | EMD 33512 | EMD33512 | Bisoprolol Fumarate | Fumarate, Bisoprolol | Bisoprolol, (-)-Isomer
Chemical Information
Molecular Formula C18H31NO4
CAS Registry Number 66722-44-9
SMILES CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Psychomotor retardation19.15.02.0020.001342%Not Available
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.002013%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.001342%
Pulmonary hypertension24.08.03.002; 22.06.01.0010.003354%
Pulmonary oedema02.05.02.003; 22.01.03.0030.003354%
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.002683%Not Available
Rash generalised23.03.13.002--Not Available
Rash maculo-papular23.03.13.0040.002683%
Rash pruritic23.03.12.0020.003354%Not Available
Raynaud's phenomenon24.04.03.0030.002013%Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.003354%
Red blood cell count decreased13.01.05.007--Not Available
Renal colic20.02.03.010--
Renal failure20.01.03.0050.003150%Not Available
Respiratory disorder22.02.07.0020.001342%Not Available
Respiratory distress22.02.01.0120.004696%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001750%
Respiratory tract haemorrhage24.07.01.036; 22.02.07.011--Not Available
Restlessness19.11.02.002; 17.02.05.0210.003354%
Retrograde ejaculation21.03.01.0060.002013%Not Available
Rhabdomyolysis15.05.05.0020.003354%
Rheumatoid arthritis10.04.06.001; 15.01.03.0010.001342%Not Available
Rhinitis11.01.13.004; 22.07.03.006--
Rhinitis allergic22.04.04.003; 10.01.04.003--
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 20 Pages